Cancer
BCR-ABL (HLA-A*02:01) GVRGRVEEI
€105.00*
Prices excl. VAT plus shipping
costs
Available, delivery time:
3 weeks
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity:
95% HPLC-MS
Caution:
For research use only. Not for use in humans.
Amount in mg
1
Product number: EP11087_1
Description
#
TechData
| Sequence: | GVRGRVEEI |
| Gene: | BCR |
| Delivery: | 3 weeks |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Human Bcr-abl 210 kD fusion protein |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | Flow Cytometry |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |
Skip product gallery
More BCR-ABL peptides
BCR-ABL 19-27 (HLA-B*27:01)
From
€105.00*
Tumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assay
BCR-ABL 926-934 (HLA-A*02:01)
From
€105.00*
In chronic myelogenous leukemia, a translocation occurs between chromosomes 9 and 22, which leads to a BCR-ABL fusion gene. This results in chimeric proteins.The nonapeptide BCR-ABL 926-934 (epitope ID 2187155) with the amino acid sequence SSKALQRPV from the junctional region of the BCR-ABLb3a2 molecule has been shown to be immunogenic. It could therefore be useful for developing a specific immunotherapy for patients with chronic myelogenous leukemia. BCR-ABL 926-934 binds to HLA-A2.1 molecules and triggers primary reactions of cytotoxic T lymphocytes in vitro.
BCR/ABL 210 kD fusion protein 259-269 (HLA-A*03:01) (HLA-A*11:01)
From
€105.00*
This peptide has high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide composed BCR-ABL 210 kD fusion protein-derived peptide of ATGFKQSSK sequence covering 259-269 and A*03:01, A*11:01 molecule.